FEATURED

AHNS 2018 Coverage

Follow our coverage of the American Head & Neck Society (AHNS) 2018 meeting in National Harbor, MD.

Fact Sheet: Bloodroot and Cancer

Bloodroot-containing products sold as a cure for cancer can be highly toxic and result in disfigurement.

Infections in Patients With CLL

Patients with CLL may have both disease-associated and systemic treatment-associated immune dysfunction, leaving them vulnerable to infection.

Ask the Experts: Treating Multiple Myeloma

Cancer Therapy Advisor asked 3 experts to weigh in on recommended treatment modalities for patients with multiple myeloma.

Ask the Experts: Treating CML

Cancer Therapy Advisor asked 3 experts to weigh in on recommended treatment modalities.

Ask the Experts: Treating MCL

Cancer Therapy Advisor asked 2 experts to weigh in on recommended treatment modalities for patients with mantle cell lymphoma.

Looking for a Job?

Access our job board to view over 1,​200 job openings throughout the US.

Treatment Regimens

A full listing of cancer treatment and drug information is available to access.

Latest Features

Infections: A Cause for Concern Among Patients With CLL

Infections: A Cause for Concern Among Patients With CLL

Patients with CLL may have both disease-associated and systemic treatment-associated immune dysfunction, leaving them vulnerable to infection.

HIV-Associated Cancers: A Paradigm Shift?

HIV-Associated Cancers: A Paradigm Shift?

Many HIV-associated cancers develop with the help of oncoviruses — some of which are sexually transmitted.

Late-Onset Toxicity Possible With Immunotherapy

Late-Onset Toxicity Possible With Immunotherapy

Postapproval studies are needed to further characterize the risk and long-term safety of immune checkpoint inhibition.

Diet and Dosage: How Much Could Patients Save?

Diet and Dosage: How Much Could Patients Save?

Knowing that food increases the absorption of some therapies presents the possibility of easily — and significantly — lowering treatment costs.

Ibrutinib and Venetoclax: A New Standard for Mantle Cell Lymphoma?

Ibrutinib and Venetoclax: A New Standard for Mantle Cell Lymphoma?

Preclinical models indicated that dual inhibition of BTK and BCL2 may be synergistic.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs